Since its inception in 2004, the Hematology Research Program (formerly known as the Hematology Research and Clinical Trials Unit or HRCTU) has brought innovative therapies to patients with blood diseases including the creation of less toxic therapies, new methods of delivering medications (intravenous vs. pill), and the evaluation of new drug combinations.
Key areas of research at Hematology Research Program are understanding how normal blood cells and stem cells become diseased or turn into cancers, and the development of safer, more effective treatments and diagnostic tests for blood diseases. Through the Program's clinical trials, patients have the opportunity to participate in studies that give them access to leading edge treatments that are yet unavailable to the masses.
Dr. Stephen Nantel, Director
- Located at Vancouver General Hospital and BC Cancer Agency
- The Program has 21 principle and affiliated investigators and approximately 14 trainees
- The Program has 35 active/ongoing clinical trials
- Since 2005, over 7,500 cell and tissue samples have been collected from nearly 1,600 patients as part of the Hematology Cell Bank of BC
- Hematology Cell Bank samples are available to VCH scientists and research clinicians for the development of new blood disease treatments and tests
- Conducted 76 clinical trials, which has provided over 600 patients with access to new treatments
Hematology Research Program
Krall Centre – Centennial Pavilion 6
Vancouver General Hospital
855 W 12th Avenue
Vancouver, BC V5Z 1M9
Phone: 604.875.4111 x 62887